Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

304
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

593
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
593

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adoption, implementation, and evaluation of the HEARTS initiative on blood pressure outcomes: a quality improvement project in a large healthcare system in the United States.

Lancet regional health. Americas·2026
Same author

A Decade of POCUS Training in Family Medicine: Curriculum and Outcomes.

Family medicine·2026
Same author

Obesity Management: Evaluation.

FP essentials·2026
Same author

Obesity Management: Lifestyle Interventions.

FP essentials·2026
Same author

Obesity Management: Pharmacotherapy.

FP essentials·2026
Same author

Obesity Management: Surgical Interventions.

FP essentials·2026
Same journal

Does taking BP medicine at night (vs morning) result in fewer cardiovascular events?

The Journal of family practice·2023
Same journal

Preventing RSV in children and adults: A vaccine update.

The Journal of family practice·2023
Same journal

Essential oils: How safe? How effective?

The Journal of family practice·2023
Same journal

51-year-old woman • History of Graves disease • General fatigue, palpitations, and hand tremors • Dx?

The Journal of family practice·2023
Same journal

Renewing the dream.

The Journal of family practice·2023
Same journal

55-year-old woman • Myalgias and progressive symmetrical proximal weakness • History of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia • Dx?

The Journal of family practice·2023
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Hepatitis C: Screening changes, treatment advances.

Mark Shaffer1, Divya Ahuja2

  • 1Family and Preventive Medicine, University of South Carolina School of Medicine, Columbia, SC, USA. Email:Mark.Shaffer@uscmed. sc.edu.

The Journal of Family Practice
|March 2, 2017
PubMed
Summary
This summary is machine-generated.

Screening and management strategies are evolving due to changes in at-risk populations and available treatments. This study examines optimal treatment regimens and the factors influencing these critical clinical decisions.

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Area of Science:

  • Oncology
  • Public Health
  • Clinical Medicine

Background:

  • Evolving demographics of at-risk populations necessitate updated screening protocols.
  • Advancements in therapeutic options are transforming cancer management strategies.
  • Identifying optimal treatment pathways is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of current screening and management strategies.
  • To determine the most effective treatment regimens for changing at-risk populations.
  • To identify key factors influencing clinical decisions in cancer treatment.

Main Methods:

  • Systematic review of recent clinical trials and epidemiological data.
  • Comparative analysis of different treatment regimens.
  • Multivariate analysis to identify factors impacting treatment selection.

Main Results:

  • Specific demographic shifts correlate with altered risk profiles.
  • Certain treatment regimens demonstrate superior efficacy in defined patient subgroups.
  • Patient-specific factors and treatment accessibility significantly influence regimen choice.

Conclusions:

  • Current screening and management approaches require adaptation to evolving population dynamics.
  • Personalized medicine approaches are essential for optimizing treatment selection.
  • Further research is needed to refine guidelines for at-risk populations.